Eli Lilly secures China approval for first oral weight loss pill

Published 1d ago · Latest report 1d ago · Product launch

Affects China and United States · Covered in 2 countries

AI summary32s readPositive

China clears Eli Lilly to launch the nation's first oral GLP-1 weight-loss pill.

China has cleared Eli Lilly's daily pill orforglipron for chronic weight management in adults. Marketed as Foundayo, it stands as the nation's inaugural approved oral GLP-1 treatment for obesity. Pharmaceutical companies are fiercely competing to enter China's expanding market for weight-loss therapies.

The regulatorChina's National Medical Products Administration officially announced the clearance.
The targetThe once-daily medication is intended for adults dealing with obesity or excess weight.

Why it matters

China represents a massive and highly lucrative market for global pharmaceutical companies racing to offer effective weight-management solutions. Securing early approval gives drug makers a vital competitive edge in establishing a dominant foothold among millions of prospective patients.

How outlets cover it

What outlets agree on

China has granted regulatory approval to Eli Lilly for its oral weight-loss medication orforglipron, marking the country's first approved oral GLP-1 treatment for obesity.

Tune your feed

Reactions